#1 Clinical Trials Search in Europe
EU – Europe
AT – Austria
HR – Croatia
CZ – Czech Republic
DK – Denmark
EE – Estonia
FI – Finland
FR – France
DE – Germany
IS – Iceland
IT – Italy
LV – Latvia
LT – Lithuania
NL – Netherlands
NO – Norway
PL – Poland
PT – Portugal
RO – Romania
SK – Slovakia
SI – Slovenia
ES – Spain
SE – Sweden
  • Find a Clinical Trial

    Search Trials by Disease

    Non-small cell lung cancer Breast cancer Plasma cell myeloma Neoplasm Neoplasm malignant Acute myeloid leukaemia Colitis ulcerative Colorectal cancer metastatic Obesity Prostate cancer Crohn's disease Colorectal cancer Ovarian cancer Dementia Alzheimer's type Hepatocellular carcinoma Breast cancer metastatic Dermatitis atopic Asthma Non-small cell lung cancer metastatic Malignant melanoma More trials…
  • Rare Diseases Treatments

    Search Trials by Disease

    Craniocerebral injury Malignant glioma Leukoencephalopathy Soft tissue sarcoma Loeys-Dietz syndrome Familial haemophagocytic lymphohistiocytosis Follicular lymphoma stage II Basal cell naevus syndrome Oesophageal adenocarcinoma stage III Vulval cancer Human papilloma virus immunisation Congenital nephrogenic diabetes insipidus Pustular psoriasis Hyperoxaluria Splenic marginal zone lymphoma More trials…

    Learn about Rare Diseases

    Ewing’s sarcoma metastatic – Trials in Disease Indolent systemic mastocytosis – Treatment Splenic marginal zone lymphoma – Treatment Kearns-Sayre syndrome – Diagnostics Mucopolysaccharidosis I Hyperoxaluria – Treatment Loeys-Dietz syndrome – Trials in Disease Epidermolysis bullosa – Treatment Pyogenic sterile arthritis pyoderma gangrenosum and acne syndrome Chondrosarcoma metastatic – Trials in Disease More diseases
  • Vaccine Clinical Trials
  • Pediatric Clinical Trials
  • Resources for Patients

    Browse Innovative Treatments

    Ly3473329 Human Vaccinia Immunoglobulin Amniotic Membrane, Human Golcadomide Delandistrogene Moxeparvovec Carcik-Cd19 Cells AZD4360 Omp64 Tipapkinogene Sovacivec Isoflurane ANGIOTENSIN II Protamine Sulfate DAPIGLUTIDE Ubiquinol Etranacogene Dezaparvovec Deoxyribonucleic Acid Prasugrel Hydrobromide Iodine (123I) Iobenguane VOXVOGANAN Lbl-007 More therapies…

    Learn about Your Condition

    Hyperparathyroidism secondary Breast proliferative changes Hepatitis B Squamous cell carcinoma Diffuse large B-cell lymphoma Exposure via breast milk Osteomyelitis Friedreich's ataxia Breast cancer stage IV Eclampsia Pemphigus Retinopathy proliferative Alveolar bone defect Sickle cell disease Plasma cell myeloma recurrent More diseases
  • Healthy Volunteers
  • Patient Guide
  • Our Partners
  • About Us
  • Contact us
  • Region
    🇪🇺 Europe
    🇦🇹 Austria
    🇭🇷 Croatia
    🇨🇿 Czech Republic
    🇩🇰 Denmark
    🇪🇪 Estonia
    🇫🇮 Finland
    🇫🇷 France
    🇩🇪 Germany
    🇮🇸 Iceland
    🇮🇹 Italy
    🇱🇻 Latvia
    🇱🇹 Lithuania
    🇳🇱 Netherlands
    🇳🇴 Norway
    🇵🇱 Poland
    🇵🇹 Portugal
    🇷🇴 Romania
    🇸🇰 Slovakia
    🇸🇮 Slovenia
    🇪🇸 Spain
    🇸🇪 Sweden

Eye Diseases

  • Study of Port Delivery System with ranibizumab given every 36 weeks in patients with neovascular age-related macular degeneration

    Recruiting

    3 1 1 1
    Investigated Diseases:
    • Neovascular age-related macular degeneration
    • Age-related macular degeneration
    Investigated Drugs:
    • Ranibizumab
    Austria Czechia Denmark France Germany Greece +3

  • Evaluation of SB-007 Safety and Efficacy in Patients with Stargardt Disease Type 1 (STGD1) Caused by ABCA4 Gene Mutations

    Recruiting

    2 1 1
    Investigated Drugs:
    • ADENO-ASSOCIATED VIRUS VECTOR SEROTYPE 8 ENCODING THE ABCA4 PROTEIN, C-REGION
    • ADENO-ASSOCIATED VIRUS VECTOR SEROTYPE 8 ENCODING THE ABCA4 PROTEIN, N-REGION
    Belgium Germany

  • Study on the Effects of Faricimab for Caucasian Patients with Polypoidal Choroidal Vasculopathy

    Recruiting

    3 1 1 1
    Investigated Diseases:
    • Polypoidal choroidal vasculopathy
    Investigated Drugs:
    • Faricimab
    Italy Portugal Spain

  • Study of Faricimab Treatment Given Every 24 Weeks in Patients with Age-Related Macular Degeneration

    Recruiting

    3 1 1 1
    Investigated Diseases:
    • Neovascular age-related macular degeneration
    Investigated Drugs:
    • Faricimab
    France Germany Italy Spain

  • Study on the Effectiveness and Safety of Sepofarsen for Patients with Leber Congenital Amaurosis Due to a Specific Genetic Mutation

    Recruiting

    3 1
    Investigated Drugs:
    • SEPOFARSEN
    Belgium France Germany The Netherlands Spain

  • Study on the Effectiveness and Safety of GAL-101 Eye Drops for Patients with Geographic Atrophy from Age-Related Macular Degeneration

    Recruiting

    2 1
    Investigated Drugs:
    • SODIUM (R)-2-(2-AMINO-3-(1H-INDOL-3- YL)PROPANAMIDO)-2-METHYLPROPANOATE-PROPAN-2-OL
    France Germany Ireland Italy
Previous Page
1 … 3 4 5 6 7 … 37
Next Page

Investigational Drugs in This Location

See which drug candidates are part of clinical trials near you. Click for detailed trial information.

Medical Conditions Being Studied in This Location

Explore diseases currently included in clinical trials near you. Click to view trials and details for each condition.

European Clinical Trials Information Network

The European Clinical Trials Information Network is transforming access to clinical trial information for patients across Europe. By overcoming language barriers, our platform allows everyone, regardless of their native language, to easily find relevant and comprehensible clinical trial data. This innovative service connects patients to cutting-edge treatments, creating a unified European community where health and progress transcend borders.

This service is not affiliated with the European Commission, the EMA, or the official CTIS system. Most information comes from publicly available international clinical-trial registries, supplemented by data from academic centres, national regulators, and commercial sponsors. We aim to keep all content accurate and up to date.

Explore the full ecosystem of clinical research in Europe.

The information provided on this website is mainly derived from international public clinical trial databases (CTIS.eu). In addition, we are including supplementary sources, such as information provided by academic centers and national regulators, as well as information supplied by commercial sponsors (pharmaceutical companies and contract research organizations). We try to ensure that the information provided is accurate and up to date.

Certain content and visual elements on this website have been generated or enhanced using artificial intelligence (AI).

The website is published by:
CTIN POLAND sp. z o.o.
with its registered office in Warsaw,
ul. rtm. Witolda Pileckiego 67/109,
02-781 Warsaw, Poland,
entered in the Register of Entrepreneurs of the National Court Register under KRS number 0001111334,
REGON: 528919042, NIP (Tax ID): 9512598637
Contact us

© 2026 CTIN Poland

Privacy Policy

Terms and Conditions

Contact

For Sites and Sponsors

Clinical Trial Locations

We use cookies

The website uses cookies to ensure the proper functioning of the site and to analyze internet traffic. Some cookies are essential for using the service and do not require consent. You can accept all cookies or use only the essential ones. Data is processed in accordance with our Privacy Policy. You have the right to withdraw your consent, access, rectify, delete, or limit the processing of your data at any time.
Numer nieprawidłowy!
Numer nieprawidłowy!